Medicare AdvantageCoverageMedium impact
MA11.004r, Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)
Independence Blue Cross·Urology·Medical Policy
Effective date
Sep 21, 2026
We identified it
Sep 22, 2026
Summary
Independence Blue Cross Medicare Advantage updated policy MA11.004r to classify the permanent nitinol urethral expansion device (ProVee System) and CPT code 52282 as Experimental/Investigational, effective 09/21/2026. This means claims for this device will not be covered or reimbursed. All other covered surgical and minimally invasive BPH treatments remain medically necessary when criteria are met.
Action Required
By September 21, 2026: Billing team must update billing software and claim submission rules to flag CPT code 52282 and ProVee System implants as non-covered/experimental for all Independence Blue Cross Medicare Advantage plans. Deny or do not submit claims for CPT 52282 and route any existing claims to manual review for denial processing. Update provider communication materials and EMR templates to reflect that ProVee System is no longer a covered treatment option under this policy. Verify that all other covered BPH procedure codes (52441, 52442, 52450, 52597, C9739, C9740) continue to process normally when medical necessity criteria are met. Failure to implement this change will result in claim denials and potential compliance issues with Independence Blue Cross Medicare Advantage.